Olmesartan-Induced Enteropathy: Case Reports and Insights From FDA Adverse Event Reporting System (FAERS)

Ilaria Mariani, Giulia Mosini, Stefania Cheli, Sofia Dinegro, Andrea Vicenzi, Cecilia Bonino, Vera Battini, Carla Carnovale, Emilio Clementi, Sonia Radice, Clinical Research, Department of Biomedical and Clinical Sciences, University Hospital Luigi Sacco, Università Degli Studi di Milano, Department of Emergency, University Hospital Luigi Sacco, Università Degli Studi di Milano, Scientific Institute, IRCCS E. Medea, Bosisio Parini

Journal of Pharmacy Practice

Published online on September 06, 2025

Abstract

Journal of Pharmacy Practice, Ahead of Print.
Olmesartan, an angiotensin II receptor blocker (ARB) approved in 2002, is used to treat hypertension, either alone or with other antihypertensive drugs. It has been frequently associated with sprue-like enteropathy, while few cases of colitis have been ...